RT Journal Article
SR Electronic
T1 A plasma proteomic signature for atherosclerotic cardiovascular disease risk prediction in the UK Biobank cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.13.24313652
DO 10.1101/2024.09.13.24313652
A1 Gupte, Trisha P.
A1 Azizi, Zahra
A1 Kho, Pik Fang
A1 Zhou, Jiayan
A1 Chen, Ming-Li
A1 Panyard, Daniel J.
A1 Guarischi-Sousa, Rodrigo
A1 Hilliard, Austin T.
A1 Sharma, Disha
A1 Watson, Kathleen
A1 Abbasi, Fahim
A1 Tsao, Philip S.
A1 Clarke, Shoa L.
A1 Assimes, Themistocles L.
YR 2024
UL http://medrxiv.org/content/early/2024/09/15/2024.09.13.24313652.abstract
AB Background While risk stratification for atherosclerotic cardiovascular disease (ASCVD) is essential for primary prevention, current clinical risk algorithms demonstrate variability and leave room for further improvement. The plasma proteome holds promise as a future diagnostic and prognostic tool that can accurately reflect complex human traits and disease processes. We assessed the ability of plasma proteins to predict ASCVD.Method Clinical, genetic, and high-throughput plasma proteomic data were analyzed for association with ASCVD in a cohort of 41,650 UK Biobank participants. Selected features for analysis included clinical variables such as a UK-based cardiovascular clinical risk score (QRISK3) and lipid levels, 36 polygenic risk scores (PRSs), and Olink protein expression data of 2,920 proteins. We used least absolute shrinkage and selection operator (LASSO) regression to select features and compared area under the curve (AUC) statistics between data types. Randomized LASSO regression with a stability selection algorithm identified a smaller set of more robustly associated proteins. The benefit of plasma proteins over standard clinical variables, the QRISK3 score, and PRSs was evaluated through the derivation of Δ AUC values. We also assessed the incremental gain in model performance using proteomic datasets with varying numbers of proteins. To identify potential causal proteins for ASCVD, we conducted a two-sample Mendelian randomization (MR) analysis.Result The mean age of our cohort was 56.0 years, 60.3% were female, and 9.8% developed incident ASCVD over a median follow-up of 6.9 years. A protein-only LASSO model selected 294 proteins and returned an AUC of 0.723 (95% CI 0.708-0.737). A clinical variable and PRS-only LASSO model selected 4 clinical variables and 20 PRSs and achieved an AUC of 0.726 (95% CI 0.712-0.741). The addition of the full proteomic dataset to clinical variables and PRSs resulted in a Δ AUC of 0.010 (95% CI 0.003-0.018). Fifteen proteins selected by a stability selection algorithm offered improvement in ASCVD prediction over the QRISK3 risk score [Δ AUC: 0.013 (95% CI 0.005-0.021)]. Filtered and clustered versions of the full proteomic dataset (consisting of 600-1,500 proteins) performed comparably to the full dataset for ASCVD prediction. Using MR, we identified 11 proteins as potentially causal for ASCVD.Conclusion A plasma proteomic signature performs well for incident ASCVD prediction but only modestly improves prediction over clinical and genetic factors. Further studies are warranted to better elucidate the clinical utility of this signature in predicting the risk of ASCVD over the standard practice of using the QRISK3 score.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a grant from the National Institutes of Health 1R01DK114183. TPG was supported by the Sarnoff Cardiovascular Research Foundation Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UKB received ethical approval from the Northwest Multicenter Research Ethics Committee and obtained informed consent from all participants at the time of recruitment. This study was conducted under UK Biobank application number 52374.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.GDF15Growth/differentiation factor 15LTBP2Latent-transforming growth factor beta-binding protein 2BCANBrevican core proteinNEFLNeurofilament light polypeptidePCSK9Proprotein convertase subtilisin/kexin type 9LPAApolipoprotein(a)IL6RInterleukin-6 receptor subunit alphaFN1FibronectinCELSR2Cadherin EGF LAG seven-pass G-type receptor 2PSCR1Proline/serine-rich coiled-coil 1SORT1Sortilin